Downstream Consequences
The mechanisms classified below are real, clinically significant, and often the immediate source of patient suffering. They are classified as consequences—not because they are unimportant, but because treating them in isolation, without addressing the upstream causes and amplifiers, cannot resolve the disease. They are the smoke, not the fire; extinguishing them brings relief but does not put out the blaze.
The distinction between amplifiers and consequences is sometimes blurry. The key difference is that amplifiers have self-reinforcing feedback loops that can maintain or worsen the disease independently, while consequences are passively generated by the disease state and would resolve if the upstream processes were corrected. In practice, some consequences have weak feedback effects (sleep fragmentation mildly impairs immune function, for example), but these effects are insufficient to maintain the disease in the absence of the primary drivers.
Persistent sickness behavior. The chronic activation of the hypothalamic sickness behavior program, detailed in Chapter Symptom-Producing Mechanisms in ME/CFS, produces much of the lived experience of ME/CFS: fatigue, malaise, cognitive impairment, pain, and social withdrawal. A specific neural instantiation of this program is the cytokine-mediated suppression of orexin neuron firing in the lateral hypothalamus, where chemogenetic reactivation of orexin neurons reverses inflammation-induced lethargy (Grossberg et al. 2011) (Section ME/CFS as Functional Narcolepsy Type 2: Cytokine-Mediated Orexin Suppression Without Autoimmune Destruction). These symptoms are generated by cytokine signaling to the brain, prostaglandin-mediated hypothalamic effects, and vagal afferent activation—not by tissue damage per se. Sickness behavior is a consequence of the upstream immune dysregulation and neuroinflammation rather than a self-sustaining independent process. If the upstream immune activation were completely suppressed, the sickness behavior program should disengage—though epigenetic consolidation of microglial activation may delay this resolution by maintaining CNS cytokine production even after peripheral immune activation normalizes.
Sleep fragmentation. The unrefreshing sleep universal in ME/CFS reflects disrupted sleep architecture: reduced slow-wave sleep (which is required for glymphatic clearance, growth hormone secretion, and memory consolidation), increased cortical arousals, and altered circadian signaling (Chapter Neurological and Neurocognitive Dysfunction). Orexin deficiency directly causes REM-gating failure and sleep fragmentation (Ito et al. 2023), and inflammation-induced orexin suppression (Grossberg et al. 2011) may contribute to ME/CFS sleep disruption (Section ME/CFS as Functional Narcolepsy Type 2: Cytokine-Mediated Orexin Suppression Without Autoimmune Destruction). While sleep disruption worsens cognitive function and impairs the restorative processes that occur during deep sleep, it is downstream of the autonomic dysfunction (which disrupts sleep-regulating circuits), neuroinflammation (which alters neurotransmitter balance in sleep centers), and hypothalamic dysregulation (which disrupts circadian rhythm generation) produced by the trigger-capable mechanisms. Improving sleep quality through pharmacological means (low-dose trazodone, suvorexant, melatonin) helps patients symptomatically but does not address the neuroinflammatory and autonomic processes that fragment sleep.
Catecholamine synthesis failure. The reduced CSF catecholamine precursors documented by Walitt et al. (Walitt et al. 2024) — DOPA reduced by approximately 50%, DOPAC and DHPG correspondingly diminished — were initially interpreted as reflecting cofactor depletion rather than primary enzymatic failure. However, the Aregawi et al. (2026) follow-up analysis refines this picture substantially (Aregawi et al. 2026). Using composite pathway indices (NE + DHPG + MHPG for noradrenergic; DA + DOPAC + HVA for dopaminergic), they demonstrated that the catecholamine deficiency is selective for the norepinephrine pathway, while the dopamine pathway is statistically indistinguishable from healthy controls. This selectivity is difficult to reconcile with a global cofactor-depletion model (e.g., BH4 deficiency), which would impair both pathways equally. Instead, it points toward a mechanism specific to the ATP-dependent step: DBH is localized within synaptic vesicles and requires an ATP-driven proton pump for vesicular uptake of dopamine. Decreased ATP availability would selectively block norepinephrine synthesis while leaving cytoplasmic dopamine metabolism intact — precisely the pattern observed. Supplementing cofactors (BH4, iron if deficient, vitamin C) may provide some benefit, but the ATP-dependent vesicular defect would require addressing the underlying energy metabolism failure for sustained improvement.
Ferroptosis susceptibility. The chronic state of oxidative stress, iron dysregulation, and glutathione depletion in ME/CFS creates conditions favorable to ferroptotic cell death (Section Ferroptosis Susceptibility). Ferroptosis is an iron-dependent form of programmed cell death driven by lipid peroxidation; it requires the convergence of free iron, depleted glutathione (the substrate for GPX4, the key anti-ferroptotic enzyme), and polyunsaturated fatty acid-rich membranes. ME/CFS provides all three conditions. Cells in affected tissues may exist at the “edge of ferroptosis”—not dying en masse, but experiencing chronic low-grade cell loss that contributes to progressive tissue damage and functional decline. This is a consequence of the upstream oxidative and metabolic environment, not an independent driver.
Deferred-cost PEM architecture. The evolutionary deferred-cost model (Section Vascular Healing Focus) proposes that PEM exploits normal physiology: the body’s evolved capacity to defer the metabolic cost of acute exertion and collect it later. In health, this mechanism enables emergency performance (fight-or-flight responses that borrow against future metabolic capacity); the deferred cost is repaid during subsequent rest with minimal consequence. In ME/CFS, the “collection” phase is amplified by broken restoration machinery: the metabolic debt incurred during exertion cannot be efficiently repaid because the restoration processes (mitochondrial repair, glycogen replenishment, oxidative damage clearance) are themselves compromised. The deferred-cost architecture is normal physiology—what makes it pathological in ME/CFS is the failure of the restoration systems. Treating the architecture (e.g., by suppressing the deferral mechanism) would be counterproductive; treating the broken restoration machinery requires addressing the upstream causes.
Table Downstream Consequences consolidates the three-tier classification of all mechanisms discussed in this chapter. The following sections provide the causal role, key evidence, and therapeutic tractability of each mechanism.
#landscape[
| Mechanism | Causal Tier | Cert. | Key Evidence | Failed Criterion | Tractability |
|---|---|---|---|---|---|
| Trigger-Capable Root Causes | |||||
| CNS energy crisis | Root cause | 0.55 | PET/SPECT hypometabolism; CSF catecholamine deficit (Walitt 2024) | Passes all 4 | Low |
| Metabolic safe mode lock | Root cause | 0.45 | Itaconate/IDO upregulation; coordinated metabolic suppression pattern | Passes all 4 | Low–Moderate |
| GPCR autoantibody cascade | Root cause | 0.45 | Elevated autoantibodies; 60% daratumumab response; endothelial dysfunction | Passes all 4 | Moderate–High |
| TRPM3 channelopathy | Root cause | 0.35 | Multi-site NK cell TRPM3 dysfunction; ubiquitous tissue expression | Passes all 4 | Low |
| Amplifier Mechanisms | |||||
| NAD+ depletion spiral | Amplifier | — | PARP/CD38 consumption; impaired de novo synthesis | Criterion 1 (precipitant) | Moderate |
| Oxidative stress cycle | Amplifier (secondary) | — | Elevated ROS markers; cardiolipin peroxidation; Nrf2 suppression | Criterion 1 (precipitant) | Moderate |
| Mast cell–energy loop | Amplifier | — | 30–60% MCAS comorbidity; neuroinflammation via CNS mast cells | Criterion 2 (PEM) | High |
| Viral reactivation \(\leftrightarrow\) immune exhaustion | Amplifier | — | Elevated EBV/HHV-6 titers; T cell exhaustion markers | Criterion 1 (precipitant) | Low–Moderate |
| Endothelial activation / microclotting | Amplifier | — | Amyloid microclots; endothelial biomarkers | Criterion 1 (precipitant) | Moderate |
| Epigenetic consolidation | Amplifier (load-bearing) | — | DNA methylation changes; histone modifications; duration-dependent entrenchment | Criterion 1 (precipitant) | Low |
| Downstream Consequences | |||||
| Sickness behavior | Consequence | — | Cytokine-mediated hypothalamic activation | All 4 (dependent) | Low–Moderate |
| Sleep fragmentation | Consequence | — | Reduced slow-wave sleep; circadian disruption | All 4 (dependent) | Moderate |
| Catecholamine synthesis failure | Consequence | — | CSF DOPA/DOPAC reduction; cofactor depletion | All 4 (dependent) | Moderate |
| Ferroptosis susceptibility | Consequence | — | Iron dysregulation; glutathione depletion; lipid peroxidation | All 4 (dependent) | Low |
| Deferred-cost PEM architecture | Consequence | — | Normal physiology exploited by broken restoration machinery | All 4 (dependent) | N/A |
:::